Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension
- 8 January 2007
- journal article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 61 (1) , 153-156
Abstract
In recent years new therapeutic options have been developed for the management of pulmonary arterial hypertension (PAH). Sitaxsentan is an oral, once daily, highly selective endothelin A receptor antagonist that recently demonstrated a positive effect on functional capacity and haemodynamics of PAH patients. The aim of this study is to evaluate the effect of sitaxsentan in the quality of life (QOL) of PAH patients. Twenty-three patients with idiopathic PAH or PAH associated to collagen vascular diseases were evaluated at baseline and after 16 weeks of treatment with sitaxsentan 100 mg orally, once daily. 6-min walk test distance (6MWD) and QOL questionnaire (QOLQ) (SF-36) were obtained at baseline and at week 16. There was a significant improvement in functional capacity evaluated by 6MWD (472 m vs. 490 m, p = 0.03) and also in the physical component of the QOLQ (p < 0.01). Evaluating each of the domains of the SF-36 QOLQ, those more related to physical capacity presented a significant increase while the domains related to the mental component presented a trend of improvement, without reaching statistical significance. Sitaxsentan improves QOL in patients with PAH mainly through the domains related to functional capacity.Keywords
This publication has 25 references indexed in Scilit:
- Health-Related Quality of Life in Patients With Pulmonary Arterial HypertensionChest, 2004
- Sitaxsentan Therapy for Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Classification of endothelin receptors and antagonists in clinical developmentClinical Science, 2002
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- ATS Statement: Guidelines for the Six-Minute Walk TestAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial HypertensionChest, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled TrialAmerican Journal of Respiratory and Critical Care Medicine, 2002
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991